Brugada Syndrome Market Research Report: By Diagnosis (Electrocardiogram, Electrophysiology (Ep) Test, Genetic Testing), Treatment (Implantable Cardioverter-Defibrillator), by End-User (Hospitals & Clinics, Diagnostic Centers) - Global Forecast Till 2023

Synopsis of the Global Brugada Syndrome Market

Brugada syndrome is a genetic condition resulting in an abnormal electrical activity within the heart, which in turn increases the risk of sudden cardiac death. In some cases, the abnormal heart rhythm often occurs when a patient is at rest and may be triggered by a fever. However, signs and symptoms of Brugada syndrome include fainting, irregular heartbeats or palpitations, and extremely fast and chaotic heartbeat. The signs and symptoms of Brugada syndrome are similar to some other heart rhythm related problems.

The global Brugada syndrome market is mainly driven by the high prevalence of heart diseases such as Brugada syndrome and others and a huge demand for diagnosis and treatment methods. Additionally, the increasing availability of diagnostic services for respiratory illness also fuels the growth of the market. Moreover, favorable reimbursement policies are likely to boost the market growth.

Many private and government insurance organizations are present in developed countries. Over 50 private insurance companies are present in the U.S. The policies cover more than 75% of the cost of the devices and treatment. For instance, under the Medicare plan in the U.S., if the average cost of single chamber devices is approximately USD 10,000, then USD 7,500 is reimbursed. Additionally, in developed countries such as the UK, Canada, Germany, and others, similar reimbursement policies are available.

The global Brugada syndrome market is expected to grow at a CAGR of 6.4% during the forecast period.

FIGURE 1: Global Brugada Syndrome Market, by Region, 2016 (%)

Source: Centers for Disease Control and Prevention, World Health Organization, population reference bureau,
Intended Audience

- Drug Manufacturers
- Drug Suppliers
- Medical Research Laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Potential Investors

Research Methodology

Segments

The global Brugada syndrome market is segmented on the basis of diagnosis, treatment, and end-user.

On the basis of diagnosis, the market is segmented into electrocardiogram, Electrophysiology (EP) test, genetic testing, and others.

On the basis of treatment, the market is segmented into implantable cardioverter-defibrillator and drug therapy. Drug therapy is further segmented into antiarrhythmic drugs, psychotropic drugs, anesthetics/analgesics, and others. Antiarrhythmic drugs are further sub-segmented into ajmaline, allapinin, ethacizin, flecainide, pilsicainide, procainamide, propafenone, and others. Psychotropic drugs are further sub-segmented into amitriptyline, clomipramine, desipramine, lithium, loxapine, nortriptiline, trifluoperazine, and others. Anesthetics/analgesics are further segmented into bupivacaine, procaine, propofol, and others.

On the basis of end-user, the market is segmented into hospitals and clinics, surgical centers, diagnostic centers, and others.

Regional Analysis of the Global Brugada Syndrome Market

The American Brugada syndrome market is segmented into two regions, namely, North America and South America. North America, being the largest market, is mainly driven by the increasing use of electrocardiogram, Electrophysiology (EP) test for the diagnosis of the disease, and huge population base diagnosed with heart-related diseases. Furthermore, the U.S. is the largest market in North America owing to the presence of a large number of market players manufacturing medications for Brugada syndrome and increasing awareness about risk factors and cases of the disease. Canada is expected to be the fastest growing market which is driven by the overall increasing demand for diagnostic medical devices with progress in the medical device sector. South America is expected to be the fastest growing market due to technologically advanced devices for diagnosis and the increasing demand for treatment options of respiratory diseases.

The European Brugada syndrome market exhibits a positive growth with an increasing emphasis on the diagnosis of heart diseases such as Brugada syndrome and others. Moreover, Germany and the UK are the major contributors to
the growth of the market. Additionally, the increasing expenditure in healthcare by major countries in Europe also accelerates the growth of the market.

Asia Pacific is expected to be the fastest growing market whose growth is attributed to a huge demand for diagnostic tests and increasing focus on early diagnosis and treatment of heart diseases. Furthermore, other factors contributing to the growth of the market are lifestyle changes, the influence of western culture among the adults, and addiction to smoking. Additionally, the increasing environmental pollution and exposure to harmful chemicals also attribute to the growth of the market.

The Middle Eastern and African market for Brugada syndrome exhibits a steady rise with an increase in the number of healthcare facilities providing treatment for chronic conditions and the flourishing growth of the medical device sector especially diagnostic devices such as MRI and CT. In the African region, the awareness about COPD is increasing, thus fueling the growth of the market.

Key Players in the Global Brugada Syndrome Market

Some of the key players in this market are GeneDx (U.S), PGxHealth LLC (U.S), Abbott (U.S), GE Healthcare (U.K), Medtronic (U.S.), Pfizer, Inc (U.S), Boston Scientific Corporation (U.S.), GlaxoSmithKline (U.K), Eli Lilly Company (U.S), Taj Pharmaceuticals Ltd (India), and others.
9.2.1.1 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 U.K.
9.3.1.4 Italy
9.3.1.5 Spain
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia Pacific
9.5 The Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of the Middle East & Africa

10 Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments

11 Company Profiles
11.1 GeneDx
11.1.1 Company Overview
11.1.2 Product Overview
11.1.3 Financials
11.1.4 SWOT Analysis
11.2 PGxHealth LLC
11.2.1 Company Overview
11.2.2 Product Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 Abbott
11.3.1 Company Overview
11.3.2 Product Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 PneumRx
11.4.1 Company Overview
11.4.2 Product/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 GE healthcare
11.5.1 Company Overview
11.5.2 Product Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.6 Medtronic
11.6.1 Company Overview
11.6.2 Product Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.7 Pfizer, Inc.
11.7.1 Overview
11.7.2 Product Overview
11.7.3 Financials
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 Others

13 MRFR Conclusion
13.1 Key Findings
13.1.1 From CEO's View Point
13.1.2 Unmet Needs of the Market
13.2 Key Companies to Watch
13.3 Prediction of the Brugada Syndrome Industry

14 Appendix

LIST OF TABLES
Table 1 Brugada Syndrome Industry Synopsis, 2017–2023
Table 2 Global Brugada Syndrome Market Estimates & Forecast, 2017–2023, (USD Million)
Table 3 Global Brugada Syndrome Market, by Region, 2017–2023, (USD Million)
Table 4 Global Brugada Syndrome Market, by Diagnosis, 2017–2023, (USD Million)
Table 5 Global Brugada Syndrome Market, by Treatment, 2017–2023, (USD Million)
Table 6 Global Brugada Syndrome Market, by End-User, 2017–2023, (USD Million)
Table 7 North America Brugada Syndrome Market, by Diagnosis, 2017–2023, (USD Million)
Table 8 North America Brugada Syndrome Market, by Treatment, 2017–2023, (USD Million)
Table 9 North America Brugada Syndrome Market, by End-User, 2017–2023, (USD Million)
Table 10 U.S. Brugada Syndrome Market, by Diagnosis, 2017–2023, (USD Million)
Table 11 U.S. Brugada Syndrome Market, by Treatment, 2017–2023, (USD Million)
Table 12 U.S. Brugada Syndrome Market, by End-User, 2017–2023, (USD Million)
Table 13 Canada Brugada Syndrome Market, by Diagnosis, 2017–2023, (USD Million)
Table 14 Canada Brugada Syndrome Market, by Treatment, 2017–2023, (USD Million)
Table 15 Canada Brugada Syndrome Market, by End-User, 2017–2023, (USD Million)
Table 16 South America Brugada Syndrome Market, by Diagnosis, 2017–2023, (USD Million)
Table 17 South America Brugada Syndrome Market, by Treatment, 2017–2023, (USD Million)
Table 18 South America Brugada Syndrome Market, by End-User, 2017–2023, (USD Million)
Table 19 Europe Brugada Syndrome Market, by Diagnosis, 2017–2023, (USD Million)
Table 20 Europe Brugada Syndrome Market, by Treatment, 2017–2023, (USD Million)
Table 21 Europe Brugada Syndrome Market, by End-User, 2017–2023, (USD Million)
Table 22 Western Europe Brugada Syndrome Market, by Diagnosis, 2017–2023, (USD Million)
Table 23 Western Europe Brugada Syndrome Market, by Treatment, 2017–2023, (USD Million)
Table 24 Western Europe Brugada Syndrome Market, by End-User, 2017–2023, (USD Million)
Table 25 Eastern Europe Brugada Syndrome Market, by Diagnosis, 2017–2023, (USD Million)
Table 26 Eastern Europe Brugada Syndrome Market, by Treatment, 2017–2023, (USD Million)
Table 27 Eastern Europe Brugada Syndrome Market, by End-User, 2017–2023, (USD Million)
Table 28 Asia Pacific Brugada Syndrome Market, by Diagnosis, 2017–2023, (USD Million)
Table 29 Asia Pacific Brugada Syndrome Market, by Treatment, 2017–2023, (USD Million)
Table 30 Asia Pacific Brugada Syndrome Market, by End-User, 2017–2023, (USD Million)
Table 31 Middle East & Africa Brugada Syndrome Market, by Diagnosis, 2017–2023, (USD Million)
Table 32 Middle East & Africa Brugada Syndrome Market, by Treatment, 2017–2023, (USD Million)
Table 33 Middle East & Africa Brugada Syndrome Market, by End-User, 2017–2023, (USD Million)

LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Brugada Syndrome Market
Figure 3 Segmentation Market Dynamics for Brugada Syndrome Market
Figure 4 Global Brugada Syndrome Market Share, by Diagnosis 2016
Figure 5 Global Brugada Syndrome Market Share, by Treatment 2016
Figure 6 Global Brugada Syndrome Market Share, by End-User, 2016
Figure 7 Global Brugada Syndrome Market Share, by Region, 2016
Figure 8 North America Brugada Syndrome Market Share, by Country, 2016
Figure 9 Europe Brugada Syndrome Market Share, by Country, 2016
Figure 10 Asia Pacific Brugada Syndrome Market Share, by Country, 2016
Figure 11 Middle East & Africa Brugada Syndrome Market Share, by Country, 2016
Figure 12 Global Brugada Syndrome Market: Company Share Analysis, 2016 (%)
Figure 13 GeneDx: Key Financials
Figure 14 GeneDx: Segmental Revenue
Figure 16 GeneDx: Geographical Revenue
Figure 17 PGxHealth LLC: Key Financials
Figure 18 PGxHealth LLC: Segmental Revenue
Figure 19 PGxHealth LLC: Geographical Revenue
Figure 20 Abbott: Key Financials
Figure 21 Abbott: Segmental Revenue
Figure 22 Abbott: Geographical Revenue
Figure 23 GE healthcare: Key Financials
Figure 24 GE healthcare: Segmental Revenue
Figure 25 GE healthcare: Geographical Revenue
Figure 26 Medtronic: Segmental Revenue
Figure 27 Medtronic: Geographical Revenue
Figure 28 Boston Scientific Corporation: Segmental Revenue
Figure 29 Boston Scientific Corporation: Geographical Revenue
Figure 30 Pfizer, Inc.: Segmental Revenue
Figure 31 Pfizer, Inc.: Geographical Revenue